Skip to Main Content

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

  • Study HIC#:2000036125
  • Last Updated:03/20/2024

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Rehema Mtawali

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range.

    Eligibility Criteria

    Inclusion Criteria:

    • Provision of signed and dated informed consent form
    • Stated willingness to comply with all study procedures and availability for the duration of the study
    • Male or female, aged 18 to ≤30 years
    • Diagnosed T1D for at least 12 months and with BMI <25 kg/m2.
    • HbA1c ≤10%
    • Clinical use of continuous glucose monitoring (CGM)
    • Any known laboratory safety parameter consistently outside the below extended laboratory ranges in the past year:
      1. Baseline creatinine >1.0mg
      2. Hypertriglyceridemia (>400 mg/dl)
      3. ALT ≥3.5 times the upper normal limit (UNL)

    Exclusion Criteria:

    • Any known laboratory safety parameter consistently outside the below extended laboratory ranges in the past year:
      Baseline creatinine >1.0mg
      Hypertriglyceridemia (>400 mg/dl)
      ALT ≥3.5 times the upper normal limit (UNL)Current use of adjunctive diabetes medication or anti-obesity medication
    • Insulin dose <0.5 units/kg/day
    • Use of lipid lowering prescription medication other than statins or omega-3 products
    • Doesn't meet MRI safety criteria or having claustrophobia
    • Known liver disease other than non-alcoholic steatosis or non-alcoholic fatty liver disease
    • Known renal impairment
    • Pregnancy or lactation, or planning to become pregnant during the study period.
    • Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation.
    • Treatment with another investigational drug within the past 1 month
    • Past medical history of or self-reported corn allergy

    Principal Investigator

    For more information about this study, including how to volunteer, contact: